ADIAL PHARMACEUTICALS, INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Adial Pharmaceuticals changed its corporate name to Azora Therapeutics, Inc., effective October 29, 2026, following its June 2026 acquisition of Azora Therapeutics. Stockholders approved conversion of Series A preferred stock (issued in the acquisition) into common stock. The company raised approximately $32 million in gross proceeds from a private placement led by Coastlands Capital, with potential for an additional $32 million upon Phase 1 initiation of lead asset AT177 (an oral AhR agonist for ulcerative colitis), planned for H1 2027. New executive leadership includes Matt Davidson (CEO, former Verrica founder) and Julie Saiki (Chief Strategy Officer, UC patient and scientist).
Why this rating
Acquisition and $32M raised represent ~5x the company's $6.5M market cap, transformative for this microcap. Clinical-stage focus and experienced leadership are positive. Execution risk on Phase 1 trial remains high.
Price action (we called it positive)
before filing · preread $5.05 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.